SAN RAMON, Calif.—To provide faster delivery to eyecare professionals and their patients, CooperVision said it has expanded its made-to-order manufacturing at its technologically advanced facility in Scottsville, N.Y. to include all Biofinity toric multifocal contact lenses for the U.S. and Canada. All trial lenses and six-packs of the brand’s most prescribed powers are now being produced at the site, with plans to manufacture 100 percent of the U.S. and Canada’s Biofinity toric multifocal six-pack volume within the next few months, the company said, noting that the expansion reduces delivery times by eliminating international shipping and customs clearance steps.

All orders to service other markets will continue to be manufactured at the company’s facility in the U.K.
 
“The process of manufacturing a contact lens that corrects for both astigmatism and presbyopia is complex, and even more so when the available prescription options are so incredibly broad,” said Doug Brayer, director of marketing, frequent replacement brands, CooperVision. “CooperVision’s continuous innovation and investment in manufacturing has not only made lenses like Biofinity toric multifocal possible, but also enables us to deliver practitioners and patients a highly customized product on an expedited timeline.”
 
 
With CooperVision’s made-to-order advantage, Biofinity toric multifocal lenses are available in more than 205,000 unique prescription options to ensure that eyecare professionals have a lens for every patient. The company pointed out that when using CooperVision’s OptiExpert app or the fitting guide, Biofinity toric multifocal has a 93 percent success rate on initial fitting to save chair time for both ECPs and patients. CooperVision, is a division of CooperCompanies (NYSE:COO).